A carregar...
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
AIMS: To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin 9, compared with ezetimibe, as add-on therapy to maximally tolerated statin therapy in high cardiovascular risk p...
Na minha lista:
| Publicado no: | Eur Heart J |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4430683/ https://ncbi.nlm.nih.gov/pubmed/25687353 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehv028 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|